Lives unaffected by cystic fibrosis

DRUG DEVELOPMENT PIPELINE

Back to the Drug Development Pipeline

MRT5005

Phase One

Phase One

Therapeutic Approach

Restore CFTR Function

MRT5005 is a new drug designed to restore CFTR function by delivering correct copies of CFTR-encoded mRNA to the lungs. mRNA is a molecule that contains genetic instructions to make proteins. Delivery of CFTR-encoded mRNA would allow the lung cells to create normally functioning CFTR protein, regardless of an individual’s specific CFTR gene mutation. This drug is delivered via inhalation.

Status

A phase 1 & 2 study to test the safety and tolerability of MRT5005 is underway.

Sponsor

This program is sponsored by Translate Bio (previously RaNA Therapeutics). It is being conducted through the Therapeutics Development Network.



Contact us about MRT5005 >